Latest Agenus News & Updates

See the latest news and media coverage for Agenus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Agenus

Cancer immunotherapy company

agenusbio.com

Last updated Today

Latest news about Agenus

In short: Agenus secured up to $340 million in private placement financing to advance late-stage colon cancer trials for its BOT+BAL combination.

Company announcements

Yesterday Agenus

Agenus announces $340M private placement to fund ROBBIN trial

The placement includes $85M upfront and up to $255M in warrants to support the Phase 3 neoadjuvant BOT+BAL study in MSS colon cancer.

July 6 Agenus

Agenus reports 33% three-year survival in MSS mCRC

The Phase 1b BOT+BAL data show 21.2-month median overall survival and a survival curve plateau.

June 25 Agenus

Agenus announces three-year survival data from Phase 1b BOT+BAL study

Data reflect an additional year of follow-up from the 123-patient cohort, to be presented at ESMO GI 2026.

June 2 Agenus

Agenus announces virtual 2026 annual shareholders meeting

The meeting will be held on June 16, 2026, in a virtual format. Shareholders can register and vote.

Media coverage

Today MSN

Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?

Agenus AGEN shares soared 82.7% in the last trading session to close at $6.12. The move was backed by solid volume with far more shares...

Today Yahoo Finance

Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?

Earlier this month, Agenus released three-year landmark Phase 1b data showing that its botensilimab plus balstilimab ...

Yesterday Yahoo Finance

AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment

Net proceeds from the financing are slated to fund a late-stage colon cancer clinical trial and...

Yesterday AFP

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of...

Never miss news about Agenus

Track Agenus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.